Onconews

By onconews

Podcast do portal onconews.com.br

destinado a oncologistas e médicos de outras especialidades envolvidos na prevenção, no diagnóstico e no tratamento do câncer.... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about Onconews:

How many episodes does Onconews have?

The podcast currently has 141 episodes available.

Onconews episodes:

August 22, 2023Omissão da radioterapia adjuvante no câncer de mama luminal A e rastreamento em mulheres canadenses de 40 a 49 anos
AVISO:
Quem segue o Podcast do Onconews nos streamings de áudio como o Spotfy, entre outros, deve fazer uma nova busca e passar a seguir a série que tem o logo com o fundo verde. A mudança ocorre para permitir a ampliação do alcance incluindo outros serviços como o Amazon Music.

Referências deste episódio. O último dessa série:
Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast
Cancer - Timothy J. Whelan, B.M., B.Ch., Sally Smith, M.D., Sameer Parpia,
Ph.D., Anthony W. Fyles, M.D., Anita Bane, M.B., Fei-Fei Liu, M.D., Eileen
Rakovitch, M.D., Lynn Chang, M.D., Christiaan Stevens, M.D., Julie Bowen, M.D.,
Sawyna Provencher, M.D., Valerie Théberge, M.D., et al., for the LUMINA Study
Investigators*. August
17, 2023. N Engl J Med 2023; 389:612-619. DOI: 10.1056/NEJMoa2302344 https://www.nejm.org/doi/full/10.1056/NEJMoa2302344

Impact of Breast Cancer Screening on 10-Year Net
Survival in Canadian Women Age 40-49 Years - Anna N. Wilkinson, MD, MSc, CCFP;
Larry F. Ellison, MSc2; Jean-Michel Billette, PhD; and Jean M. Seely, MD, FRCPC
- DOI: 10.1200/JCO.23.00348 Journal of Clinical Oncology - Published online
August 04, 2023. https://ascopubs.org/doi/full/10.1200/JCO.23.00348
...more
22min
August 02, 2023Upregulation do HER2 após terapia endócrina neoadjuvante no câncer de mama HR+/HER2-negativo e sobrevida em 5 Anos no estudo WSG-ADAPT-TP
Referências:
Chaudhary
LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten
C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang
Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2
Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After
Short-Term Neoadjuvant Endocrine Therapy. Res Sq [Preprint]. 2023 Apr
7:rs.3.rs-2777910. doi: 10.21203/rs.3.rs-2777910/v1. Update in: Breast Cancer
Res Treat. 2023 Jul 17;: PMID: 37066270; PMCID: PMC10104267. https://www.researchsquare.com/article/rs-2777910/v1

Harbeck
N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J,
Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just
M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K,
Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT
investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without
Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early
Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023
Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. PMID:
36809046. https://ascopubs.org/doi/10.1200/JCO.22.01816

--
...more
24min
June 28, 2023Associação de HER2DX com pCR e sobrevida no câncer de mama HER2+ e prevalência de câncer de mama em cirurgiãs ortopédicas
Referências:
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C,
Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M,
Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Dieci MV, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa
P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín
M, Prat A, Tolaney SM, Association of HER2DX with pathological complete
response and survival outcomes in HER2-positive breast cancer, Annals of
Oncology (2023), doi: https://doi.org/10.1016/j.annonc.2023.05.012.
Ou https://www.annalsofoncology.org/article/S0923-7534(23)00721-4/fulltext

Chou, Loretta B. MD; Johnson, Brianna MD; Shapiro,
Lauren M. MD, MS; Pun, Stephanie MD; Cannada, Lisa K. MD; Chen, Antonia F. MD,
MBA; Valone, Lindsey C. MD; Van Nortwick, Sara S. MD; Ladd, Amy L. MD; Finlay,
Andrea K. PhD. Increased
Prevalence of Breast and All-cause Cancer in Female Orthopaedic Surgeons.
JAAOS: Global Research and Reviews 6(5):e22.00031, May 2022. | DOI:
10.5435/JAAOSGlobal-D-22-00031 https://journals.lww.com/jaaosglobal/Fulltext/2022/05000/Increased_Prevalence_of_Breast_and_All_cause.10.aspx
...more
25min
June 20, 2023Desfechos e fatores prognósticos no carcinoma lobular invasivo triplo-negativo (TN) e ctDNA na doença luminal e TN
Referências:
Joshi, U., Budhathoki, P., Gaire, S. et al. Clinical outcomes and prognostic factors in
triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res
Treat 200, 217–224 (2023). https://doi.org/10.1007/s10549-023-06959-3
ou https://link.springer.com/article/10.1007/s10549-023-06959-3

Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E,
Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ,
Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin
A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ,
DeMichele AM, Rugo HS, van 't Veer LJ. Clinical significance and biology of circulating tumor DNA in high-risk
early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008.
Epub 2023 May 4. PMID: 37146605. https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00134-4
...more
21min
June 15, 2023Câncer de mama no ASCO 2023 – Parte 2
Referências:
Primary outcome analysis of the phase 3 SONIA trial (BOOG
2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6
(CDK4/6) inhibitors for patients with hormone receptor-positive (HR+),
HER2-negative (HER2-) advanced breast cancer (ABC). DOI:
10.1200/JCO.2023.41.17_suppl.LBA1000 Journal of Clinical Oncology 41, no.
17_suppl (June 10, 2023) LBA1000-LBA1000. Published online June 07, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1000?role=tab

A randomized controlled trial comparing primary tumor
resection plus systemic therapy with systemic therapy alone in metastatic
breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017. DOI:
10.1200/JCO.2023.41.16_suppl.523 Journal of Clinical Oncology 41,
no. 16_suppl (June 01, 2023) 523-523. Published online May 31, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.523
...more
26min
June 06, 2023 Câncer de mama no ASCO 2023
Referências:

LBA500:
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant
treatment in patients with HR+/HER2− early breast cancer. 

LBA506: 3-year invasive disease-free
survival (iDFS) of the strategy-based, randomized phase II PHERGain trial
evaluating chemotherapy (CT) de-escalation in human epidermal growth factor
receptor 2-positive (HER2[+]) early breast cancer (EBC).

--
...more
25min
May 31, 2023PET-CT na doença localmente avançada e dissecção de linfonodo axilar em homens com câncer de mama invasivo
Referências:
Chung, S.H., de Geus, S.W.L., Shewmaker, G. et al. Axillary Lymph
Node Dissection is Associated with Improved Survival Among Men with Invasive
Breast Cancer and Sentinel Node Metastasis. Ann Surg Oncol (2023). https://doi.org/10.1245/s10434-023-13475-7
ou https://link.springer.com/article/10.1245/s10434-023-13475-7

Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, Blanchette P, Cil TD,
Arnaout A, Chan A, Levine MN. Impact of 18F-Labeled
Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus
Conventional Staging in Patients With Locally Advanced Breast Cancer. J Clin
Oncol. 2023 May 26:JCO2300249. doi: 10.1200/JCO.23.00249. Epub ahead of print. PMID:
37235845. https://ascopubs.org/doi/abs/10.1200/JCO.23.00249
...more
23min
May 24, 2023Estudos WSG-TP-II e MAINTAIN avaliam eficácia da terapia endócrina em diferentes cenários e combinações
Referências:
Gluz O, Nitz UA, Christgen M, et al. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs
De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive
Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical
Trial. JAMA Oncol. Published online May 11, 2023.
doi:10.1001/jamaoncol.2023.0646 https://jamanetwork.com/journals/jamaoncology/article-abstract/2804892

Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik
Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou
E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD,
Hershman DL. Randomized Phase II Trial of Endocrine Therapy With or Without
Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in
Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 May 19:JCO2202392.
doi: 10.1200/JCO.22.02392. Epub ahead of print. PMID: 37207300. https://ascopubs.org/doi/abs/10.1200/JCO.22.02392
...more
25min
May 17, 2023Terapia endócrina para prevenção primária e secundária e adesão às recomendações de estilo de vida
Referências:
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast
Cancer - Alison Laws, MD, MPH and Rinaa S. Punglia, MD, MPH - DOI: 10.1200/JCO.23.00455 Journal of Clinical Oncology - Published online May 01,
2023. - PMID: 37126767 https://ascopubs.org/doi/abs/10.1200/JCO.23.00455

Cannioto RA, Attwood KM, Davis EW, et al. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Netw Open. 2023;6(5):e2311673. doi: 10.1001/jamanetworkopen.2023.11673 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804477

--
...more
25min
May 11, 2023Revisão do estudo monarchE e valor clínico da expressão do receptor de progesterona no câncer de mama luminal
Referências:
Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggests
no evidence to support use of adjuvant abemaciclib in women with breast cancer.
Lancet Oncol. 2023 May 2:S1470-2045(23)00165-1. doi:
10.1016/S1470-2045(23)00165-1. Epub ahead of print. PMID: 37146621. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00165-1/fulltext

Johnston
SRD, Tolaney SM, O'Shaughnessy J, Rastogi P, Harbeck N, Martin M. Review of the
monarchE trial suggests no evidence to support use of adjuvant abemaciclib in
women with breast cancer - Authors' reply. Lancet Oncol. 2023 May
2:S1470-2045(23)00214-0. doi: 10.1016/S1470-2045(23)00214-0. Epub ahead of
print. PMID: 37146620. https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(23)00214-0.pdf

Lashen
AG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone
receptor expression in luminal breast cancer: A study of a large cohort with
long-term follow-up. Cancer. 2023 Apr 15;129(8):1183-1194. doi:
10.1002/cncr.34655. Epub 2023 Jan 18. PMID: 36653923. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34655
...more
30min

FAQs about Onconews:

How many episodes does Onconews have?

The podcast currently has 141 episodes available.